Shares of Knight Therapeutics Inc (TSE:GUD) have earned a consensus recommendation of “Buy” from the seven brokerages that are presently covering the firm, reports. One investment analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is C$10.15.

GUD has been the subject of a number of research analyst reports. TD Securities raised their target price on Knight Therapeutics from C$9.50 to C$10.00 in a research note on Friday, August 10th. Bloom Burton restated an “accumulate” rating on shares of Knight Therapeutics in a research note on Friday.

GUD opened at C$8.30 on Friday. Knight Therapeutics has a 52 week low of C$7.38 and a 52 week high of C$8.81.

Knight Therapeutics (TSE:GUD) last released its earnings results on Thursday, November 8th. The company reported C$0.03 EPS for the quarter, meeting the Zacks’ consensus estimate of C$0.03. The firm had revenue of C$3.22 million during the quarter, compared to analysts’ expectations of C$2.26 million. On average, analysts anticipate that Knight Therapeutics will post 0.130000001435583 EPS for the current fiscal year.

About Knight Therapeutics

Knight Therapeutics Inc operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its commercialized products include Movantik to treat opioid induced constipation; Impavido, an alkyllysophospholipid analogue drug for visceral and cutaneous Leishmaniasis; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; and Flat Tummy Tea, a herbal detox tea.

Featured Article: What are the most popular ETFs

Analyst Recommendations for Knight Therapeutics (TSE:GUD)

Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with's FREE daily email newsletter.